CME Group (CME) Gets a Buy from Morgan Stanley

Morgan Stanley analyst Michael Cyprys maintained a Buy rating on CME Group today and set a price target of $362.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Cyprys covers the Financial sector, focusing on stocks such as Nasdaq, Intercontinental Exchange, and Brookfield Corporation. According to TipRanks, Cyprys has an average return of 2.5% and a 49.80% success rate on recommended stocks.

In addition to Morgan Stanley, CME Group also received a Buy from TD Cowen’s William Katz in a report issued yesterday. However, on April 8, KBW resumed coverage with a Hold rating on CME Group (NASDAQ: CME).

Based on CME Group’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.65 billion and a net profit of $1.17 billion. In comparison, last year the company earned a revenue of $1.53 billion and had a net profit of $874.6 million

Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CME in relation to earlier this year. Last month, Elizabeth Cook, a Director at CME sold 1,000.00 shares for a total of $320,000.00.